| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
22,585 |
17,669 |
$999K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
8,363 |
6,879 |
$847K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,975 |
7,407 |
$561K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
13,351 |
10,124 |
$404K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,740 |
2,194 |
$138K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
355 |
344 |
$28K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
476 |
476 |
$26K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
192 |
192 |
$14K |
| 92015 |
Determination of refractive state |
777 |
777 |
$11K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
58 |
58 |
$6K |
| T1502 |
Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit |
39 |
12 |
$3K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
25 |
24 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
81 |
71 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
137 |
127 |
$2K |
| 99215 |
Prolong outpt/office vis |
14 |
12 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
13 |
12 |
$693.23 |
| 96127 |
|
208 |
207 |
$181.43 |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
43 |
38 |
$103.37 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
363 |
341 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
748 |
565 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
1,215 |
1,135 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
660 |
603 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
30 |
26 |
$0.00 |
| 1101F |
|
15 |
13 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
1,756 |
1,620 |
$0.00 |
| 4320F |
|
1,912 |
1,459 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
4,821 |
3,810 |
$0.00 |
| 4004F |
|
1,987 |
1,496 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
100 |
93 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
162 |
147 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
54 |
54 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
65 |
60 |
$0.00 |